Fang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fang Liu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Fu-Ying Li
School of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation
3 shared publicationsHan Mo
School of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation
3 shared publicationsJin-Yang Li
School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, Shandong 252059, PR China
3 shared publicationsShun-Hu Gao
School of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation
3 shared publicationsXiao-Han Sun
School of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation
3 shared publicationsXin-Yu Hu
School of Pharmaceutical Sciences and Food Engineering, and State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation
3 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1374
Development and Evaluation of a Novel Inhalable Liposomal Powder Co-Encapsulating ASSNAC and Pirfenidone via Spray Freeze-Drying for Targeted Pulmonary Fibrosis Therapy
Background: Pulmonary fibrosis (PF) is a progressive lung disease with limited therapies. Oral Pirfenidone (PFD), an approved anti-fibrotic, shows poor lung bioavailability and significant toxicity. S-Allylmercapto-N-acetylcysteine (ASSNAC) has been demonstrated to possess significant anti-inflammatory and antioxidant properties. Methods: In this study, dry powder inhaler formulations (DPIs) co-encapsulating ASSNAC and PFD in liposomes are reported. The formulation was prepared via spray freeze-drying (SFD) using L-leucine as both a cryoprotectant and a surface morphology modifier. The interfacial enrichment of L-leucine during atomization and freezing created a hydrophobic, corrugated surface that lowered particle surface energy, prevented liquid/solid bridge formation, and reduced hygroscopicity. Results: The resulting liposomal powders exhibited optimal aerosol performance: fine particle fraction (FPF) of 61.08% ± 2.45% and mass median aerodynamic diameter (MMAD) of 2.22 ± 0.11 µm. Cellular studies demonstrated that dual-loaded liposomes were efficiently taken up by Beas-2B and HFL-1 cells, with no cytotoxicity (cell viability > 90%) and negligible hemolysis. In the TGF-β1-induced in vitro fibrosis model, the combined treatment exerted prominent therapeutic effects. This regimen preserved normal epithelial morphology, accelerated wound repair, suppressed fibroblast invasiveness, and lowered the expression levels of Collagen I, Collagen III, and α-SMA. In bleomycin-induced pulmonary fibrosis rats, inhaled ASSNAC + PFD liposomal powder markedly relieved lung tissue injury and collagen accumulation. It restored redox balance and lowered pulmonary TGF-β1, hydroxyproline and collagen III levels. The formulation blocked TGF-β1 signaling and fibrotic gene expression. Conclusions: Pulmonary administration avoids oral pirfenidone-induced liver and stomach toxicity. Collectively, the ASSNAC + PFD co-encapsulated liposomal dry powder produced by SFD represents a safe and efficacious therapeutic strategy for PF.
- 31 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1374
Open AccessDevelopment and Evaluation of a Novel Inhalable Liposomal Powder Co-Encapsulating ASSNAC and Pirfenidone via Spray Freeze-Drying for Targeted Pulmonary Fibrosis Therapy
Background: Pulmonary fibrosis (PF) is a progressive lung disease with limited therapies. Oral Pirfenidone (PFD), an approved anti-fibrotic, shows poor lung bioavailability and significant toxicity. S-Allylmercapto-N-acetylcysteine (ASSNAC) has been demonstrated to possess significant anti-inflammatory and antioxidant properties. Methods: In this study, dry powder inhaler formulations (DPIs) co-encapsulating ASSNAC and PFD in liposomes are reported. The formulation was prepared via spray freeze-drying (SFD) using L-leucine as both a cryoprotectant and a surface morphology modifier. The interfacial enrichment of L-leucine during atomization and freezing created a hydrophobic, corrugated surface that lowered particle surface energy, prevented liquid/solid bridge formation, and reduced hygroscopicity. Results: The resulting liposomal powders exhibited optimal aerosol performance: fine particle fraction (FPF) of 61.08% ± 2.45% and mass median aerodynamic diameter (MMAD) of 2.22 ± 0.11 µm. Cellular studies demonstrated that dual-loaded liposomes were efficiently taken up by Beas-2B and HFL-1 cells, with no cytotoxicity (cell viability > 90%) and negligible hemolysis. In the TGF-β1-induced in vitro fibrosis model, the combined treatment exerted prominent therapeutic effects. This regimen preserved normal epithelial morphology, accelerated wound repair, suppressed fibroblast invasiveness, and lowered the expression levels of Collagen I, Collagen III, and α-SMA. In bleomycin-induced pulmonary fibrosis rats, inhaled ASSNAC + PFD liposomal powder markedly relieved lung tissue injury and collagen accumulation. It restored redox balance and lowered pulmonary TGF-β1, hydroxyproline and collagen III levels. The formulation blocked TGF-β1 signaling and fibrotic gene expression. Conclusions: Pulmonary administration avoids oral pirfenidone-induced liver and stomach toxicity. Collectively, the ASSNAC + PFD co-encapsulated liposomal dry powder produced by SFD represents a safe and efficacious therapeutic strategy for PF.
- Open Access
- 28 May 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (22) , 32732-32740
An Antibacterial “Drug–Drug” Cocrystal of Trimethoprim with Sulfathiazole Achieving Synchronized Dual-Drug Release and Pharmacokinetics
Achieving synchronized release and absorption of multiple active pharmaceutical ingredients with disparate properties has long been a critical challenge in the development of combination formulations. Multidrug cocrystals offer a promising strategy to address this issue. As a classic antibacterial combination, trimethoprim (TMP) and sulfathiazole (STZ) are widely used in conventional therapy. This study reports a drug–drug cocrystal composed of the two ingredients. The TMP-STZ cocrystal was characterized by SCXRD, PXRD, DSC-TG, and IR spectroscopy. Furthermore, its hygroscopicity, solubility, dissolution, and in vivo pharmacokinetics were systematically evaluated. The results demonstrate that the pronounced initial solubility difference between TMP and STZ was effectively balanced through cocrystallization, leading to consistent dissolution rates. These in vitro modifications enabled synchronized and enhanced pharmacokinetic profiles for the two drugs in vivo. The 110 min TMAX gap between TMP and STZ was eliminated (shifting from 50/160 min in the mixture to a unified 90 min in the cocrystal). These results represent a significant advancement in the application of crystal engineering to pharmacological outcomes and greatly facilitate the exploration of novel antibacterial cocrystal formulations.
- 28 May 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (22) , 32732-32740
Open AccessAn Antibacterial “Drug–Drug” Cocrystal of Trimethoprim with Sulfathiazole Achieving Synchronized Dual-Drug Release and Pharmacokinetics
Achieving synchronized release and absorption of multiple active pharmaceutical ingredients with disparate properties has long been a critical challenge in the development of combination formulations. Multidrug cocrystals offer a promising strategy to address this issue. As a classic antibacterial combination, trimethoprim (TMP) and sulfathiazole (STZ) are widely used in conventional therapy. This study reports a drug–drug cocrystal composed of the two ingredients. The TMP-STZ cocrystal was characterized by SCXRD, PXRD, DSC-TG, and IR spectroscopy. Furthermore, its hygroscopicity, solubility, dissolution, and in vivo pharmacokinetics were systematically evaluated. The results demonstrate that the pronounced initial solubility difference between TMP and STZ was effectively balanced through cocrystallization, leading to consistent dissolution rates. These in vitro modifications enabled synchronized and enhanced pharmacokinetic profiles for the two drugs in vivo. The 110 min TMAX gap between TMP and STZ was eliminated (shifting from 50/160 min in the mixture to a unified 90 min in the cocrystal). These results represent a significant advancement in the application of crystal engineering to pharmacological outcomes and greatly facilitate the exploration of novel antibacterial cocrystal formulations.
- Open Access
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Two kaempferol-piperazine polymorphic cocrystals and the comparative analysis in optimizing solubility and pharmacokinetics
Polymorphism is an important but frequently neglected aspect in cocrystal research. In this work, aiming to improve the solubility and bioavailability of kaempferol (KAE), the highly soluble excipient piperazine (PIP) was selected as CCF, fortunately creating two KAE-PIP polymorphic cocrystals, namely KAE-PIP 2:1 cocrystal (Form I) and KAE-PIP 2:3 cocrystal (Form II). Their structures, morphologies and stabilities were characterized using SCXRD, PXRD, FT-IR, SEM, DSC-TGA and DVS. Meanwhile, the in vitro solubility behavior and in vivo pharmacokinetics of the cocrystals were systematically evaluated. The equilibrium solubility, dissolution rate, and oral bioavailability of KAE in cocrystals showed a maximum increase of 33.8-fold, 10.6-fold, and 1.9-fold, respectively. Form II outperformed Form I in terms of optimization efficacy, and the structure-activity relationships were further analyzed comparatively. These findings advance the clinical application of KAE and provide an intriguing case for the potentially widespread polymorphism in cocrystals.
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTwo kaempferol-piperazine polymorphic cocrystals and the comparative analysis in optimizing solubility and pharmacokinetics
Polymorphism is an important but frequently neglected aspect in cocrystal research. In this work, aiming to improve the solubility and bioavailability of kaempferol (KAE), the highly soluble excipient piperazine (PIP) was selected as CCF, fortunately creating two KAE-PIP polymorphic cocrystals, namely KAE-PIP 2:1 cocrystal (Form I) and KAE-PIP 2:3 cocrystal (Form II). Their structures, morphologies and stabilities were characterized using SCXRD, PXRD, FT-IR, SEM, DSC-TGA and DVS. Meanwhile, the in vitro solubility behavior and in vivo pharmacokinetics of the cocrystals were systematically evaluated. The equilibrium solubility, dissolution rate, and oral bioavailability of KAE in cocrystals showed a maximum increase of 33.8-fold, 10.6-fold, and 1.9-fold, respectively. Form II outperformed Form I in terms of optimization efficacy, and the structure-activity relationships were further analyzed comparatively. These findings advance the clinical application of KAE and provide an intriguing case for the potentially widespread polymorphism in cocrystals.
- 11 March 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 674, 125461
The self-fluorescence verification and intracellular imaging of nanocrystals imbedded with aggregation-induced emission luminescent materials
- 11 March 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 674, 125461
The self-fluorescence verification and intracellular imaging of nanocrystals imbedded with aggregation-induced emission luminescent materials
- Open Access
- 19 May 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 187, 106469
First cocrystal of esculetin: Simultaneously optimized in vitro/vivo properties and antioxidant effect
- 19 May 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 187, 106469
Open AccessFirst cocrystal of esculetin: Simultaneously optimized in vitro/vivo properties and antioxidant effect
- 3 January 2023
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 23 (2) , 885-891
Hepatoprotective Pyrazinamide–Baicalein Cocrystal with a Rare Ratio of 7:3
- 3 January 2023
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 23 (2) , 885-891
Hepatoprotective Pyrazinamide–Baicalein Cocrystal with a Rare Ratio of 7:3
- 1 November 2021
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1243
A cocrystal for effectively reducing the hepatotoxicity of ethionamide
- 1 November 2021
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1243
A cocrystal for effectively reducing the hepatotoxicity of ethionamide
- 28 January 2020
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 20 (3) , 2064-2073
Sustained-Release Dual-Drug Ternary Salt Cocrystal of Piperazine Ferulate with Pyrazinamide: Synthesis, Structure, and Hirshfeld Surface Analysis
- 28 January 2020
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 20 (3) , 2064-2073
Sustained-Release Dual-Drug Ternary Salt Cocrystal of Piperazine Ferulate with Pyrazinamide: Synthesis, Structure, and Hirshfeld Surface Analysis
- 8 June 2018
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 18 (7) , 3729-3733
Protective Effects of Quercetin against Pyrazinamide Induced Hepatotoxicity via a Cocrystallization Strategy of Complementary Advantages
- 8 June 2018
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 18 (7) , 3729-3733
Protective Effects of Quercetin against Pyrazinamide Induced Hepatotoxicity via a Cocrystallization Strategy of Complementary Advantages